Tumor Genomic Profiling denied as experimental or investigational by Humana?

Humana's specific coverage criteria for tumor genomic profiling are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Tumor Genomic Profiling as Experimental

Humana may classify a genomic profiling test as experimental or investigational when its internal coverage policy has not yet recognized a specific assay — or its use for a particular cancer type or clinical scenario — as established standard of care. This denial language can be applied to broad comprehensive genomic profiling panels, RNA-based fusions tests, or liquid biopsy assays that are newer to clinical use even when FDA authorization exists.

This denial is frequently worth contesting. Many tumor genomic profiling tests have received FDA authorization (including Breakthrough Device designation or companion diagnostic approval) and are actively recommended in major oncology guidelines for specific indications. The "experimental" label in a coverage policy may lag behind current evidence, and that gap is exactly what an appeal can address.

## Federal Appeal Framework

Under ACA Section 2719, non-grandfathered plans must provide internal appeal and access to independent external review by an accredited independent review organization (IRO). External review is particularly powerful for experimental denials because the IRO applies current clinical evidence standards, not just the insurer's internal policy. File your internal appeal first — typically within 180 days of the denial — then request external review within approximately 4 months of the final internal denial. Expedited review is available when treatment cannot be delayed without serious health consequences. ERISA plans carry equivalent rights under Section 503.

## Concrete Appeal Steps

1. Obtain the exact policy language Humana used to classify the test as experimental. 2. Request the date that policy was last reviewed or updated. 3. Compile current guideline and regulatory documentation supporting the test for your specific indication. 4. Have your oncologist submit a detailed medical-necessity letter addressing each element of the experimental criteria. 5. If the internal appeal is denied, escalate immediately to independent external review.

## Documentation to Gather

• Diagnosis and indication: Pathology, staging, cancer type, and any biomarker results already available.
• FDA status documentation: Evidence of FDA authorization for the specific assay or platform being requested.
• Guideline support: Reference from the applicable NCCN guideline (or equivalent specialty society) recommending genomic profiling for your cancer type and line of therapy — your oncologist should confirm your case meets that guideline's criteria.
• Oncologist medical-necessity letter: Should directly address Humana's experimental criteria point by point, citing current clinical evidence for the test's utility in your specific context.
• Peer-reviewed literature: Your oncologist or a patient advocate may attach recent literature demonstrating clinical utility, particularly if your cancer type is specifically addressed.

## Criteria-Mapping Structure

List every sub-criterion in Humana's experimental/investigational definition. Map each to a specific document in your record: FDA clearance letter, guideline recommendation, and oncologist attestation. This structured mapping forces the reviewer to address each element individually rather than relying on a blanket classification.